Cadence Pharmaceuticals, Inc., et al. v. Innopharma Licensing LLC, et al., C.A. No. 14-1225 – LPS, July 8, 2016.

Stark, C. J. Claim construction opinion issues regarding three terms from two patents. A Markman hearing took place on May 9, 2016.

The disputed technology relates intravenous pharmaceutical formulations. The following terms were considered:

  1. “free radical scavenger and free radical antagonist”
  2. “ascorbic acid derivatives”
  3. “preserving for a prolonged period”